Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$618.46 USD
-5.75 (-0.92%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$618.46 USD
-5.75 (-0.92%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
What's in Store for Patterson Companies' (PDCO) Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect sluggishness at Dental segment.
Here's Why You Should Invest in LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.
Cooper Companies (COO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter performance is likely to reflect weak performance by CVI and CSI.
Medtronic's (MDT) Cryoablation Suited for Patients With PAF
by Zacks Equity Research
Medtronic's (MDT) cryoablation therapy's superiority for the treatment of PAF over currently available AAD treatment gets reflected in trial results.
Medtronic (MDT) Sees Trend Rebound Amid Coronavirus Crisis
by Zacks Equity Research
Medtronic's (MDT) procedure volumes start to recover in multiple markets globally.
5 Solid Dividend Growth Stocks to Buy Now
by Sweta Killa
Dividend investing has been gaining immense popularity amid low rates and super-easy monetary policy.
Hologic Updates Breast Biopsy System to Enhance Workflow
by Zacks Equity Research
Hologic (HOLX) introduces features to update Brevera Breast Biopsy System in order to transform patient experience and enhance workflow.
Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) core Subscription business segment performs impressively in Q2.
Bruker Rides on MALDI Launches Amid Coronavirus-Led Crisis
by Zacks Equity Research
For higher specific detection of the SARS-CoV-2 virus, Bruker (BRKR) launches luoroType SARS-CoV-2 plus next-generation 6-plex PCR assay.
Phibro (PAHC) Q4 Earnings Fall Short of Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) core Animal Health segment was aided by the Osprey Biotechnics acquisition despite a dismal overall performance in Q4 due to pandemic-led business disruptions.
AMN Healthcare's Advanced Mobile App to Aid Travel Clinicians
by Zacks Equity Research
AMN Healthcare's (AMN) new version of AMN Passport will benefit travel clinicians.
Hologic's Acessa Health Buyout to Broaden GYN Surgical Line
by Zacks Equity Research
Hologic's (HOLX) newly-acquired product line is set to complement its market-leading MyoSure products for hysteroscopic removal of fibroids.
Align Technology (ALGN) Strong on Robust Customer Adoption
by Zacks Equity Research
Align Technology (ALGN) treats the one millionth patient from the APAC region, highlighting the Invisalign system's continued adoption.
Allscripts Enhances Healthcare Innovation With Patent Program
by Zacks Equity Research
Allscripts (MDRX) continues to advance healthcare innovation by earning five new application patents.
Here's Why You Should Hold on to DENTSPLY (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY (XRAY) continues to gain traction from its solid focus on R&D leading to product innovation, which continues to be a key catalyst.
Medtronic's (MDT) Q1 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
Barring Respiratory, Gastrointestinal & Renal, Medtronic (MDT) registers dismal performance in all business segments and geographies in Q1.
Insulet (PODD) Banks on Omnipod Uptake Amid Coronavirus Woes
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.
Amedisys & BrightStar Ink Agreement to Expand Personal Care
by Zacks Equity Research
Amedisys (AMED) strengthens Personal Care business reach by entering into an agreement with BrightStar.
QIAGEN (QGEN) to Launch COVID-19 Antibody Test in the US
by Zacks Equity Research
QIAGEN's (QGEN) latest antibody test complements its array of COVID-19 testing solutions in an economical way to detect immune responses in people who have been exposed to the SARS-CoV-2 virus.
Here's Why You Should Invest in Fresenius Medical Stock Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services.
Top Stock Reports for JNJ, Procter & Gamble & Thermo Fisher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Procter & Gamble (PG) and Thermo Fisher (TMO).
Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
ASCO Recommends Myriad Genetics' Test to Treat Ovarian Cancer
by Zacks Equity Research
Myriad Genetics' (MYGN) myChoice CDx test gets included in ASCO's latest recommendations for advanced ovarian cancer patients.
Medtronic's (MDT) Evolut TAVR Label Expansion Gets FDA Nod
by Zacks Equity Research
Medtronic's (MDT) Low Risk Bicuspid Study shows bicuspid patients implanted with Evolut TAVR had low rates (1.3%) of all-cause mortality.
TeleFlex Banks on Urolift Sales Amid Coronavirus-Led Debacle
by Zacks Equity Research
The acquired business of Teleflex (TFX), NeoTract has been performing impressively lately.